Showing 11,701 - 11,720 results of 11,859 for search '(( 5 ng decrease ) OR ( 100 ((((we decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 0.69s Refine Results
  1. 11701

    Data_Sheet_1_Secular Trends in the Incidence of and Mortality Due to Alzheimer’s Disease and Other Forms of Dementia in China From 1990 to 2019: An Age-Period-Cohort Study and Join... by Yongliang Gao (11381418)

    Published 2021
    “…</p>Results<p>The age-standardized incidence and mortality rates per 100,000 population were 103.83 (95% UI, 87.93–118.87) and 23.32 (95% UI, 5.66–61.31), respectively, for dementia in 2019. …”
  2. 11702

    DataSheet_2_Causal analysis between altered levels of interleukins and obstructive sleep apnea.pdf by Minhan Yi (417990)

    Published 2022
    “…</p>Results<p>Nine different interleukins—IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, IL-17, IL-18, and IL-23—were elevated in OSA compared with control to varying degrees, ranging from 0.82 to 100.14 pg/ml, and one interleukin, IL-10, was decreased by 0.77 pg/ml. …”
  3. 11703

    Image_3_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  4. 11704

    Data_Sheet_2_Genomic Surveillance of Ceftriaxone-Resistant Escherichia coli in Western New York Suggests the Extended-Spectrum β-Lactamase blaCTX-M-27 Is Emerging on Distinct Plasm... by Heba H. Mostafa (3097494)

    Published 2020
    “…Isolates were collected from both inpatients and outpatients and from urine and sterile-sites over a 2 month period in 2017 or throughout the year, respectively. …”
  5. 11705

    DataSheet_1_Causal analysis between altered levels of interleukins and obstructive sleep apnea.pdf by Minhan Yi (417990)

    Published 2022
    “…</p>Results<p>Nine different interleukins—IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, IL-17, IL-18, and IL-23—were elevated in OSA compared with control to varying degrees, ranging from 0.82 to 100.14 pg/ml, and one interleukin, IL-10, was decreased by 0.77 pg/ml. …”
  6. 11706

    Image_2_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  7. 11707

    Table_3_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.docx by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  8. 11708

    Image_1_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  9. 11709

    Data_Sheet_1_Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis.pdf by Sha Fu (445944)

    Published 2021
    “…The alterations in clinical and biochemical parameters before and after taking sacubitril-valsartan (generally 50–100 mg b.i.d) were investigated, and safety was also assessed. …”
  10. 11710

    Image_6_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  11. 11711

    Data Sheet 1_Valve-in-valve transcatheter aortic valve replacement (TAVR) leads to lower device success compared to TAVR in native stenosis.pdf by Michael Paukovitsch (16428786)

    Published 2025
    “…</p>Methods<p>Outcomes of consecutive patients treated with ViV-TAVR (N = 100) at our tertiary heart center between 2014 and 2022 were compared to TAVR (N = 2216) in native valves.…”
  12. 11712

    Image_4_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  13. 11713

    Supplementary file 1_Comparative analysis of accuracy and completeness in standardized database generation for complex multilingual lung cancer pathological reports: large language... by Hao Hang (7037264)

    Published 2025
    “…</p>Results<p>This study analyzed 1,390 structured pathology databases: 1,300 from 100 Chinese cases (generated by 10 clinicians and three LLMs) and 90 from 30 TCGA English reports. …”
  14. 11714

    Table_1_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.docx by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  15. 11715

    Image_5_Global, regional, and national years lived with disability due to blindness and vision loss from 1990 to 2019: Findings from the Global Burden of Disease Study 2019.TIF by Shasha Li (139491)

    Published 2022
    “…Purpose<p>This study aimed to provide a comprehensive assessment of burden estimates and the secular trend of blindness and vision loss, as measured by years lived with disability (YLDs), at the global, regional, and national levels.…”
  16. 11716

    Data_Sheet_1_Genomic Surveillance of Ceftriaxone-Resistant Escherichia coli in Western New York Suggests the Extended-Spectrum β-Lactamase blaCTX-M-27 Is Emerging on Distinct Plasm... by Heba H. Mostafa (3097494)

    Published 2020
    “…Isolates were collected from both inpatients and outpatients and from urine and sterile-sites over a 2 month period in 2017 or throughout the year, respectively. …”
  17. 11717

    Predicted fitness and predicted prevalence. by Taj Azarian (659326)

    Published 2020
    “…<p><b>A</b>, Relationship between predicted fitness and observed prevalence change from pre- to post-vaccine among 31 strains, in each case summing to 100%. …”
  18. 11718

    Effects of Gas Compositions on Tuning the Kinetics of CH<sub>4</sub>/CO<sub>2</sub> Hydrates with 1,3-Dioxolane: Implication for Hydrate-Based Biogas Storage by Yuanxin Yao (4884769)

    Published 2025
    “…A key to the application of hydrate-based biogas storage (primary components as CH<sub>4</sub> and CO<sub>2</sub>) lies in elucidating the mechanism of the slow kinetics and seeking solutions to enhance the kinetics. …”
  19. 11719

    Image_1_Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with... by Jin-Kai Feng (11197404)

    Published 2022
    “…</p>Results<p>As of the data cutoff on 30 August 2021, the median follow-up time was 10.0 (3.9–28.4) months. A total of 39 eligible patients were included. …”
  20. 11720